Cybin (CYBN) and Its Competitors Financial Review

Cybin (NYSE:CYBN) is one of 443 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Cybin to related businesses based on the strength of its valuation, institutional ownership, profitability, analyst recommendations, earnings, risk and dividends.

Profitability

This table compares Cybin and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-109.05%	-97.85%
Cybin Competitors	-8,581.07%	-107.97%	-23.29%

Valuation and Earnings

This table compares Cybin and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cybin	N/A	-$35.93 million	-46.25
Cybin Competitors	$148.01 million	-$13.29 million	-13.98

Cybin’s rivals have higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Cybin has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Cybin’s rivals have a beta of 1.26, indicating that their average share price is 26% more volatile than the S&P 500.

Institutional and Insider Ownership

17.9% of Cybin shares are held by institutional investors. Comparatively, 29.2% of shares of all “Biotechnology” companies are held by institutional investors. 15.0% of Cybin shares are held by insiders. Comparatively, 25.7% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings for Cybin and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0	0	3	0	3.00
Cybin Competitors	734	2179	5081	56	2.55

Cybin presently has a consensus price target of $50.50, indicating a potential upside of 445.95%. As a group, “Biotechnology” companies have a potential upside of 10.92%. Given Cybin’s stronger consensus rating and higher possible upside, analysts clearly believe Cybin is more favorable than its rivals.

Summary

Cybin rivals beat Cybin on 9 of the 13 factors compared.

About Cybin

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.